IQ Chaikin US Small Cap ETF (CSML) Is At $28.04 Formed Wedge; ANI Pharmaceuticals, Inc. (ANIP) Had 3 Bullish Analysts

February 4, 2018 - By Shannon Black

Among 6 analysts covering ANI Pharma (NASDAQ:ANIP), 3 have Buy rating, 0 Sell and 3 Hold. Therefore 50% are positive. ANI Pharma had 19 analyst reports since July 31, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 16 by Canaccord Genuity. The stock has “Outperform” rating by Oppenheimer on Friday, August 5. The stock of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) earned “Buy” rating by TH Capital on Monday, September 28. The rating was maintained by Roth Capital with “Hold” on Thursday, November 2. The stock of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has “Buy” rating given on Thursday, December 7 by Canaccord Genuity. The company was initiated on Friday, November 13 by Standpoint Research. The rating was upgraded by Oppenheimer to “Perform” on Tuesday, July 19. The firm earned “Hold” rating on Tuesday, May 24 by Standpoint Research. Canaccord Genuity maintained ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) rating on Wednesday, August 9. Canaccord Genuity has “Buy” rating and $6000 target. The firm earned “Buy” rating on Wednesday, September 2 by TheStreet. See ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) latest ratings:

07/12/2017 Broker: Canaccord Genuity Rating: Buy New Target: $75.0 Maintain
02/11/2017 Broker: Roth Capital Rating: Hold New Target: $64.0 Maintain
16/10/2017 Broker: Canaccord Genuity Rating: Buy Maintain
09/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $60.0000 Maintain

IQ Chaikin US Small Cap ETF (CSML) formed wedge up with $29.16 target or 4.00% above today’s $28.04 share price. IQ Chaikin US Small Cap ETF (CSML) has $352.91M valuation. The ETF decreased 2.27% or $0.65 during the last trading session, reaching $28.04. About 48,525 shares traded. IQ Chaikin US Small Cap ETF (NASDAQ:CSML) has 0.00% since February 4, 2017 and is . It has underperformed by 16.70% the S&P500.

Investors sentiment increased to 1.69 in 2017 Q3. Its up 0.63, from 1.06 in 2017Q2. It improved, as 16 investors sold ANI Pharmaceuticals, Inc. shares while 26 reduced holdings. 22 funds opened positions while 49 raised stakes. 6.31 million shares or 1.29% less from 6.39 million shares in 2017Q2 were reported. State Of Wisconsin Investment Board reported 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Connecticut-based Thomson Horstmann & Bryant has invested 0.11% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Perkins Cap Mngmt Inc reported 1.09% of its portfolio in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Amer Grp owns 6,467 shares. Renaissance Tech Ltd Llc owns 290,300 shares or 0.02% of their US portfolio. California State Teachers Retirement Sys holds 12,981 shares or 0% of its portfolio. 7,280 are held by Proshare Advsrs Limited Liability Co. Weiss Asset Mngmt Limited Partnership owns 155,089 shares. Georgia-based Advisory Services Networks Ltd Liability Corp has invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Moreover, Ranger Inv Mngmt L P has 0.15% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). 2,270 were reported by Mason Street Advsrs Ltd Co. Metropolitan Life Ins Co New York invested in 0% or 5,784 shares. Vanguard Gru Inc has 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). State Street owns 271,593 shares. Chicago Equity Partners Ltd Liability Corp reported 22,570 shares.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States. The company has market cap of $708.71 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations. It has a 94.81 P/E ratio. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.

The stock decreased 9.07% or $6.07 during the last trading session, reaching $60.87. About 191,157 shares traded or 36.85% up from the average. ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has declined 0.02% since February 4, 2017 and is downtrending. It has underperformed by 16.72% the S&P500.